Bepotastine controlled-release - Hanlim Pharmaceutical
Alternative Names: BELION; Bepotastine salicylate; Bepotastine sustained-release; HL 151Latest Information Update: 10 Mar 2021
At a glance
- Originator Hanlim Pharmaceutical
- Class Antiallergics; Antiasthmatics; Antihistamines; Antipruritics; Butyric acids; Chlorobenzenes; Eye disorder therapies; Piperidines; Pyridines; Skin disorder therapies; Small molecules
- Mechanism of Action Histamine H1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic urticaria; Perennial allergic rhinitis; Pruritus
Most Recent Events
- 10 Mar 2021 Launched for Chronic-urticaria in South Korea (PO) before March 2021 (Hanlim Pharmaceutical's website, March 2021)
- 10 Mar 2021 Launched for Perennial allergic rhinitis in South Korea (PO) before March 2021 (Hanlim Pharmaceutical's website, March 2021)
- 10 Mar 2021 Launched for Pruritus in South Korea (PO) before March 2021 (Hanlim Pharmaceutical's website, March 2021)